Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity

Status Active, not recruiting

Clinical Trial Summary

Aim: Pemphigus vulgaris (PV) is a rare, life-threatening autoimmune bullous disease that can involve the skin and mucous membranes, characterized by intraepidermal bullae and eroded lesions caused by rupture of the bullae. The aim of this study is to research the relationship of the findings obtained with Tzanck smear, which is an inexpensive and easy method, with disease activity and its prognostic importance in the clinical course in PV patients. Material and Methods: Pemphigus patients who visited to Goztepe Prof. Dr. Suleyman Yalcın City Hospital, Dermatology Clinic will be included in our study. Pemphigus disease area index (PDAI), Tzanck smear findings from the lesions and desmoglein levels during routine follow-up of patients with pemphigus vesicle/bulla/erosion will be evaluated. In the evaluation of Tzanck smear preparations, the entire slide will be scanned, acantholytic cell count performed and scored 1 to 4 accordingly (1 point: 1-3 cells, 2 points: 4-10 cells, 3 points:11-20, 4 points: >21 cells or cell clusters). Anti-desmoglein antibody levels will be analyzed by using enzyme-linked immunosorbent assay (ELISA) method.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05338112
Study type	Observational [Patient Registry]
Source	Istanbul Medeniyet University
Contact
Status	Active, not recruiting
Phase
Start date	January 1, 2022
Completion date	April 15, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05635266` - A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting	`NCT04117529` - Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus	N/A
Completed	`NCT03334058` - A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus	Phase 2
Terminated	`NCT03239470` - Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus	Phase 1
Completed	`NCT00606749` - Use of KC706 for the Treatment of Pemphigus Vulgaris	Phase 2
Terminated	`NCT00429533` - Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris	Phase 2
Recruiting	`NCT05594472` - Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid	Phase 3
Completed	`NCT02383589` - A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)	Phase 3
Withdrawn	`NCT03780166` - A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris	Phase 2
Recruiting	`NCT04096222` - Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
Not yet recruiting	`NCT03177213` - Serum IL-21 Levels in Patients With Pemphigus Vulgaris	N/A
Completed	`NCT00135720` - Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris	Phase 2
Completed	`NCT00063752` - Safety Study of PI-0824 to Treat Pemphigus Vulgaris	Phase 1
Terminated	`NCT03075904` - A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)	Phase 1/Phase 2
Terminated	`NCT04598477` - A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)	Phase 3
Completed	`NCT02704429` - A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris	Phase 2
Completed	`NCT00626678` - Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone	Phase 2
Completed	`NCT06167408` - Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
Recruiting	`NCT05303272` - A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)	Phase 4
Completed	`NCT04540133` - Dexamethasone Solution and Dexamethasone in Mucolox™	Phase 2